Delocamten: Difference between revisions – Wikipedia

Delocamten
Other names	MYK-224; BMS-986435
	(6S,7S)-6-Fluoro-7-(2-fluoro-5-methylphenyl)-3-(oxan-4-yl)-5,6,7,8-tetrahydro-1H-pyrido[2,3-d]pyrimidine-2,4-dione ;
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Formula	C19H21F2N3O3
Molar mass	377.392 g·mol−1
3D model (JSmol)
	CC1=CC(=C(C=C1)F)[C@H]2[C@H](CC3=C(N2)NC(=O)N(C3=O)C4CCOCC4)F ;
	InChI=1S/C19H21F2N3O3/c1-10-2-3-14(20)12(8-10)16-15(21)9-13-17(22-16)23-19(26)24(18(13)25)11-4-6-27-7-5-11/h2-3,8,11,15-16,22H,4-7,9H2,1H3,(H,23,26)/t15-,16-/m0/s1 ; Key:NPPSFOUMKWFJKX-HOTGVXAUSA-N ;

Content deleted Content added

Revision as of 07:01, 18 October 2025

Cardiac myosin inhibitor developed by Bristol Myers Squibb

Pharmaceutical compound

Delocamten (development code MYK-224) is a small-molecule cardiac myosin inhibitor developed by Bristol Myers Squibb for hypertrophic cardiomyopathy.^[1]^[2]^[3]

^ Lehman, Sarah J.; Crocini, Claudia; Leinwand, Leslie A. (June 2022). “Targeting the sarcomere in inherited cardiomyopathies”. Nature Reviews Cardiology. 19 (6): 353–363. doi:10.1038/s41569-022-00682-0. ISSN 1759-5010. PMC 9119933. PMID 35304599.
^ Sebastian, Sneha Annie; Padda, Inderbir; Lehr, Eric J.; Johal, Gurpreet (September 2023). “Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy”. American Journal of Cardiovascular Drugs. 23 (5): 519–532. doi:10.1007/s40256-023-00599-0. PMID 37526885. S2CID 260348901.
^ Packard, Elizabeth; de Feria, Alejandro; Peshin, Supriya; Reza, Nosheen; Owens, Anjali Tiku (December 2022). “Contemporary Therapies and Future Directions in the Management of Hypertrophic Cardiomyopathy”. Cardiology and Therapy. 11 (4): 491–507. doi:10.1007/s40119-022-00283-5. PMC 9652179.

@@ Line 73: / Line 73: @@
 [[Category:Cardiac myosin inhibitors]]
 [[Category:Pyridopyrimidines]]
+[[Category:2-Fluorophenyl compounds]]